ArticleUrology2025
Prostate Specific Antigen Testing and Prostate Cancer Diagnosis Rates Among Transgender and Non-Binary Patients: Retrospective Review of a Single-Institution Experience.
Article in Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo characterize prostate-specific antigen (PSA) testing patterns, diagnosis, and treatment and management of prostate cancer in transgender and non-binary patients designated male at birth (TGNB DMAB) at a single tertiary care institution.
methodsWe retrospectively reviewed all patient encounters from March 2019 to February 2021 to identify TGNB DMAB eligible for PSA screening per American Urological Association guidelines. This cohort was analyzed to determine the rate of PSA testing, referral patterns, recommendations, and overall patterns of clinical care.
resultsAmong 216 TGNB DMAB patients identified, 86 (39.8%) had at least 1 PSA during eligible screening years. Median PSA at initial evaluation was 0.16 ng/mL (interquartile range < 0.04-1.14 ng/mL), with significant differences between patients on gender-affirming hormonal therapy or prior orchiectomy (P <.001). In the testing cohort, 45 (52.3%) patients continued PSA testing or further workup after initial evaluation, and 7 (8.1%) patients underwent prostate biopsy. Four (4.5%) were diagnosed with prostate cancer. On logistic regression, Black/African-American race was associated with decreased odds of undergoing any PSA testing (odds ratio 0.51, 95% confidence interval 0.25-1.01, P = .054).
conclusionThe PSA testing rate among TGNB DMAB patients is low compared to published rates among cisgender men. Race may also influence PSA testing patterns in this population; however, further studies are required to validate our result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.